Cui B, Song L, Wang Q, Li K, He Q, Wu X, et al. Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors. Signal Transduct Target Ther. 2023;8:366 pubmed publisher

Ueno D, Vasquez J, Sule A, Liang J, Van Doorn J, Sundaram R, et al. Targeting Krebs-cycle-deficient renal cell carcinoma with Poly ADP-ribose polymerase inhibitors and low-dose alkylating chemotherapy. Oncotarget. 2022;13:1054-1067 pubmed publisher

Kumar A, Grams T, Bloom D, Toth Z. Signaling Pathway Reporter Screen with SARS-CoV-2 Proteins Identifies nsp5 as a Repressor of p53 Activity. Viruses. 2022;14: pubmed publisher

Menendez D, Anand J, Murphy C, Bell W, Fu J, Slepushkina N, et al. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity. Oncotarget. 2022;13:332-346 pubmed publisher

Demetriadou C, Raoukka A, Charidemou E, Mylonas C, Michael C, Parekh S, et al. Histone N-terminal acetyltransferase NAA40 links one-carbon metabolism to chemoresistance. Oncogene. 2021;: pubmed publisher

McCann J, Vasilevskaya I, McNair C, Gallagher P, Neupane N, de Leeuw R, et al. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes. Oncogene. 2021;: pubmed publisher

Zhang C, Martinez Ledesma E, Gao F, Zhang W, Ding J, Wu S, et al. Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. Am J Cancer Res. 2019;9:1734-1745 pubmed

Walia M, Taylor S, Ho P, Martin T, Walkley C. Tolerance to sustained activation of the cAMP/Creb pathway activity in osteoblastic cells is enabled by loss of p53. Cell Death Dis. 2018;9:844 pubmed publisher

di Gennaro A, Damiano V, Brisotto G, Armellin M, Perin T, Zucchetto A, et al. A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ. 2018;25:2165-2180 pubmed publisher

Junk D, Vrba L, Watts G, Oshiro M, Martinez J, Futscher B. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. Neoplasia. 2008;10:450-61 pubmed